Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSR-042 combinations in advanced/metastatic cancer
NCT03307785Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of dostarlimab in cancer, metastatic cancer and non-small cell lung cancer (NSCLC) (11 arms). Primary endpoints: Dose-limiting Toxicity at 21 days and Treatment-emergent Adverse Events up to 28.5 months. Started Oct 2017; status: completed.
02
Drugs
dostarlimab
03
Conditions
cancermetastatic cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03307785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307785.